SingHealth Duke-NUS Institute of Precision Medicine

SingHealth Duke-NUS Institute of PRecIsion Medicine (PRISM) is the Academic Medical Center’s flagship initiative in precision medicine, a discipline where medical treatments and procedures are tailored to individual patients, based on their detailed genetic, molecular and clinical profiles. Through precision medicine, PRISM seeks to improve patient outcomes by identifying which patient populations are likely to benefit from specific treatments, while avoiding treatment-related toxicities.

Jointly funded and supported by SingHealth and Duke-NUS, PRISM will build upon previous SingHealth/Duke-NUS successes in precision medicine research and clinical delivery, to become “A Global Leader in Improving Patient Care through Precision Medicine, integrating Discovery, Innovation and Implementation”.

Previous PRISM accomplishments include the discovery of gene mutations causing breast fibroademonas, a condition associated with 10per cent of all women (Lim et al., 2014 Nature Genetics), and genetic variants associated with heart disease (Roberts et al., 2015 Science Translational Medicine).

Working with SingHealth investigators, PRISM have also successfully launched mainstream genetic tests for eye disease and inherited cardiac conditions. The PRISM team has successfully secured multiple National Medical Research Council STAR fellowships, industry collaborations, and scientific awards (local and international), including the President’s Science Award.

 

Current signature programmes of PRISM include:

a)      SPECTRA - a multi-dimensional database of healthy Asian normality incorporating genomic, clinical, lifestyle, and imaging data. Targeting 5,000 healthy volunteers, SPECTRA will serve as an invaluable reference database for disease-oriented studies at SingHealth/Duke-NUS and across the nation.

 

b)      PRISM suites – Working with clinical genetics experts, PRISM will establish custom-designed facilities for integrating detailed medical phenotypes with genomic information to identify individuals and families at risk for disease. Such facilities will prove essential for subsequent initiatives focused on disease prevention.

Both programmes are developed in partnership with the National Heart Research Institute Singapore (NHRIS). We actively welcome additional collaborations and partnerships from academia and industry to co-develop precision medicine in Singapore and the region.